Hyperscale Data lifts preliminary Q3 revenue estimate
Hyperscale Data lifts preliminary Q3 revenue estimate(摘要待生成)
Aramark (ARMK) Q4 Earnings and Revenues Beat Estimates - Zacks Investment Research
Aramark (ARMK) Q4 Earnings and Revenues Beat Estimates - Zacks Investment Research(摘要待生成)
Mizuho lowers Gemini Space Station stock price target on revenue decline
Mizuho lowers Gemini Space Station stock price target on revenue decline(摘要待生成)
Blackstone Digital: Q3 Earnings Snapshot - Yahoo Finance
Blackstone Digital: Q3 Earnings Snapshot - Yahoo Finance(摘要待生成)
Intel Faces Proposed Shareholder Class Action After Sharp Share Drop
Investors led by a Michigan pension fund reportedly filed a proposed securities-fraud class action in federal court in San Jose, alleging Intel concealed the effects of a sustained PC-market downturn. [[fact:fact-ewuov8gtm]] The shareholders allege Intel failed to disclose from late July through late October that falling PC sales and inventory buildup would weigh on revenue. [[fact:fact-jvnurb4h4]] CEO Lip-Bu Tan and CFO David Zinsner are named as co-defendants. [[fact:fact-i9m81pg28]] The proposed class covers investors who bought Intel shares from July 23 through October 29 and suffered losses, and seeks unspecified monetary damages. [[fact:fact-xq8moqpyr]] Intel had not publicly responded to the case as of the article’s publication. [[fact:fact-0o4qcuxpk]] After the earnings release, Intel shares fell 28.6% in one day, erasing about $140 billion in market value. [[fact:fact-6kzdhjolw]]
Freeport-McMoran 8-K (8.01): other events
Freeport-McMoRan said its 48.76%-owned subsidiary PT Freeport Indonesia intends to offer U.S. dollar-denominated senior notes to refinance existing debt and for general corporate purposes; terms and interest rate will be set at pricing, and the notes would be included in Freeport-McMoRan’s consolidated debt.
Morgan Stanley and H.C. Wainwright reiterated VKTX Buy ratings
On Nov. 16, 2026, Michael Ulz of Morgan Stanley reiterated Buy with a $95 target; Joseph Pantginis of H.C. Wainwright reiterated Buy with a $102 target. The page listed consensus among 21 analysts as Strong Buy, with a $95.32 average target; it did not show prior targets for these actions.
Lucid Capital raised its HELP target to $79 from $52 and retained Buy
On Nov. 16, 2026, Lucid Capital raised its price target to $79 from $52, kept Buy, and increased its HLP003 probability-of-success estimate to 70% from 45% after APPROACH results. The firm attributed the day’s share-price selloff to investor misunderstanding of the treatment modality and indication.
SemiAnalysis Cuts AI Compute and Capex Forecasts
SemiAnalysis reportedly cut its forecasts for AI accelerator shipments, capex, HBM demand and power demand in the coming years. [[fact:fact-37vj2k9ze]] Its 2028 global AI accelerator capex forecast was reduced by 28%. [[fact:fact-9wp4hwqri]] Its 2029 global AI accelerator capex forecast was reduced by 41%. [[fact:fact-484hmju84]] Its 2030 global AI accelerator capex forecast was reduced by 40%. [[fact:fact-fg7gv6j9t]] Its cumulative forecast for accelerator logic wafer shipment area from 2026 through 2030 was cut by 17%. [[fact:fact-f9dp8c4xa]]
8-K - Instil Bio, Inc. (0001789769) (Filer)
8-K - Instil Bio, Inc. (0001789769) (Filer)(摘要待生成)
8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)(摘要待生成)
Treasury yields climbed as inflation and Fed commentary raised rate concerns
In the week ended Nov. 13, the 10-year Treasury yield rose 27.8 basis points to 5.135%; First Trust cited hotter inflation data and hawkish Fed comments. October CPI rose 0.4% month over month and 4.1% year over year; October PPI rose 0.3% and 6.5% year over year.
Freeport-McMoRan's Indonesian Joint Venture Announces Planned Notes Offering
Freeport-McMoRan's Indonesian joint venture has unveiled plans for a new notes offering.
VKTX shares fell despite new VK2735 data
On Nov. 16, 2026, VKTX was down about 5% at $27.75 when Benzinga published. The article said the Nov. 15 VENTURE analysis added detail rather than a new headline; Viking had previously reported up to 14.7% mean weight loss at 13 weeks. It also noted shares were below the 50-day and 200-day moving averages.
Summit Therapeutics 8-K (8.01, 9.01): other events
Summit Therapeutics said the FDA issued a Complete Response Letter rejecting ivonescimab’s BLA in its current form, citing lack of statistically significant overall-survival improvement; the HARMONi trial met its progression-free-survival endpoint.
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study of HLP003
Helus Pharma announced it will host a webcast on November 16, 2026, to reveal topline results from its Phase 3 APPROACH clinical trial evaluating HLP003 as an adjunctive treatment for major depressive disorder.
Helus Pharma reported fiscal Q2 2027 results and business updates
On Nov. 16, 2026, Helus reported $171.1 million cash as of Sept. 30, 2026; quarterly net loss was $103.1 million vs. $33.7 million a year earlier, and operating cash use was $35.3 million vs. $34.5 million. It appointed Michael Halstead CEO, reported APPROACH enrollment complete, and said the HLP004 Phase 2 GAD study is expected to start Q1 2027, enrolling about 144 participants.
Helus Pharma announced positive Phase 3 APPROACH results for HLP003
On Nov. 16, 2026, Helus reported Phase 3 results in 222 adults with MDD: at Week 6, MADRS fell 19.5 points with HLP003 vs. 11.9 with placebo (difference −7.6; p<0.0001; effect size 0.653); at Week 12, difference was −7.0 (p<0.0001). Response at Week 6: 56.3% vs. 28.2%; remission: 50.9% vs. 18.2%. Three treatment-related serious adverse events; no new safety signals. EMBRACE topline expected 4Q 202
Alpha Tau files 6-K covering REGAIN investor presentation
On November 16, 2026, Alpha Tau held a previously announced investor call about REGAIN results and furnished the presentation as Exhibit 99.1.
Tyson Foods, 8-K (2.02, 9.01): reported results of operations
Tyson Foods reported fiscal 2026 sales of $56.4 billion, GAAP operating income of $1.1 billion and adjusted EPS of $3.44; fourth-quarter sales were $14.6 billion, while GAAP EPS was a loss of $0.22.
Bright Horizon completes acquisition of NorthWestern Energy, begins trading as NYSE:HZN
Bright Horizon completes acquisition of NorthWestern Energy, begins trading as NYSE:HZN(摘要待生成)
Medline shareholders launch 60 million share offering
Medline shareholders launch 60 million share offering(摘要待生成)
苹果首款折叠屏手机 iPhone Duo 中国官网送货上门时间更新,从明年 1 月提前至 12 月交付
苹果首款折叠屏手机 iPhone Duo 中国官网送货上门时间更新,从明年 1 月提前至 12 月交付(摘要待生成)